Israeli hashish inhaler firm Syqe Medical has confirmed that it’s shedding 50 staff representing one third of its workforce. Syqe has developed inhaling applied sciences to manage measured and constant doses of medical hashish. The corporate was based in 2011 by Perry Davidson and is managed by CEO Hagit Kamin.
Davidson based the corporate to resolve one of many main issues with hashish – the shortage of uniformity between totally different doses. Even when the hashish itself will be replicated, which means that the crops are at all times the identical and processed in the identical means, a deeper inhalation can change the best way the substance impacts sufferers, introducing a component of unpredictability, which may hurt the standard of therapy. Syqe’s inhaler was developed to permit for a exact and measured dose, and within the course of has been capable of obtain effectiveness even with small doses.
RELATED ARTICLES
In 2019-2021, there was nice enthusiasm out there about the potential for administering hashish in a fashion just like prescribed drugs, and Syqe’s expertise was some of the promising within the subject. At this time, the corporate nonetheless experiences income, however the emphasis on measured and exact inhalation is simply a really particular area of interest out there.
The corporate at present stresses not solely dose measurements, but additionally the potential for utilizing its product to realize outcomes with a comparatively low dosage, whereas minimizing uncomfortable side effects.
Cooperation in Israel and Australia
A number of months in the past, the corporate introduced a collaboration with the Australian Division of Veterans’ Affairs (DVA), through which the division absolutely sponsored Syqe’s inhaler. The approval follows Syqe’s collaboration with Israel’s Ministry of Protection, through which the inhaler has been supplied to hundreds of sufferers, disabled throughout navy service, and affected by power ache and post-traumatic stress dysfunction (PTSD). Syqe had a earlier settlement in Australia, through which its inhaler is supplied to victims of labor accidents.
It was beforehand reported that Syqe was to be offered to tobacco firm Philip Morris, which is certainly one of its traders together with Retallix founders Barry Shaked and Brian Cooper, OurCrowd, Shavit Capital, the Martin Bauer Group’s PRM funding arm and others. Philip Morris does have an choice to progressively purchase Syqe based mostly on milestones.
Syqe mentioned, “Syqe is adjusting the corporate’s construction throughout the second part of the medical trial and is accordingly making changes to the workforce construction, primarily within the improvement division. Specializing in the medical course of is a big a part of realizing the corporate’s targets, together with FDA approval, and accordingly, the corporate will deepen its sources on this space. As well as, Saiki will proceed to broaden its actions in sponsored markets, together with Israel.”
Printed by Globes, Israel enterprise information – en.globes.co.il – on July 17, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
